FA
AZN icon

FDx Advisors’s AstraZeneca AZN Stock Holding History

FDx Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$898K Sell
4,554
-252
-5% -$48.6K 0.29% 64
2025
Q4 		$884K Buy
4,806
+1,215
+34% +$213K 0.45% 38
2025
Q3 		$592K Sell
3,591
-178
-5% -$26.9K 0.18% 82
2025
Q2 		$527K Sell
3,769
-1,941
-34% -$272K 0.16% 90
2025
Q1 		$839K Sell
5,710
-361
-6% -$52.2K 0.27% 62
2024
Q4 		$795K Buy
6,071
+44
+0.7% +$6.16K 0.23% 72
2024
Q3 		$939K Sell
6,027
-254
-4% -$41K 0.26% 68
2024
Q2 		$980K Sell
6,281
-3,022
-32% -$455K 0.27% 67
2024
Q1 		$1.26M Sell
9,303
-3,834
-29% -$508K 0.19% 117
2023
Q4 		$1.77M Sell
13,137
-364
-3% -$47.3K 0.14% 161
2023
Q3 		$1.83M Sell
13,501
-2,114
-14% -$289K 0.15% 138
2023
Q2 		$2.23M Buy
15,615
+1,752
+13% +$258K 0.12% 174
2023
Q1 		$1.88M Hold
13,863
– – 0.08% 202
2022
Q4 		$1.88M Sell
13,863
-1,754
-11% -$220K 0.08% 202
2022
Q3 		$1.71M Sell
15,617
-1,113
-7% -$141K 0.08% 207
2022
Q2 		$2.21M Buy
+16,730
New +$2.2M 0.08% 199
2022
Q1 		– Sell
-25,730
Closed -$3M – 834
2021
Q4 		$3M Sell
25,730
-1,550
-6% -$182K 0.08% 181
2021
Q3 		$3.28M Sell
27,280
-70
-0.3% -$8.15K 0.1% 148
2021
Q2 		$3.28M Buy
27,350
+5,789
+27% +$635K 0.11% 141
2021
Q1 		$2.14M Sell
21,561
-6,145
-22% -$618K 0.08% 174
2020
Q4 		$2.77M Sell
27,706
-2,349
-8% -$249K 0.11% 140
2020
Q3 		$3.29M Sell
30,055
-2,458
-8% -$273K 0.15% 118
2020
Q2 		$3.44M Buy
32,513
+3,141
+11% +$324K 0.18% 111
2020
Q1 		$2.62M Buy
29,372
+8,442
+40% +$795K 0.17% 115
2019
Q4 		$2.09M Sell
20,930
-1,927
-8% -$181K 0.12% 145
2019
Q3 		$2.04M Buy
22,857
+489
+2% +$42.4K 0.14% 128
2019
Q2 		$1.85M Buy
22,368
+14,448
+182% +$1.13M 0.07% 205
2019
Q1 		$640K Sell
7,920
-3,194
-29% -$252K 0.03% 403
2018
Q4 		$844K Sell
11,114
-12,889
-54% -$1.01M 0.07% 206
2018
Q3 		$1.9M Sell
24,003
-16,709
-41% -$1.26M 0.07% 207
2018
Q2 		$2.86M Sell
40,712
-4,409
-10% -$317K 0.1% 160
2018
Q1 		$3.16M Sell
45,121
-33,040
-42% -$2.29M 0.09% 176
2017
Q4 		$5.42M Buy
78,161
+6,310
+9% +$426K 0.15% 112
2017
Q3 		$4.87M Buy
71,851
+12,919
+22% +$816K 0.13% 128
2017
Q2 		$4.02M Buy
58,932
+4,416
+8% +$288K 0.12% 149
2017
Q1 		$3.4M Buy
54,516
+19,235
+55% +$1.12M 0.1% 185
2016
Q4 		$1.93M Buy
35,281
+2,414
+7% +$137K 0.06% 292
2016
Q3 		$2.16M Buy
32,867
+24,342
+286% +$1.59M 0.09% 189
2016
Q2 		$515K Buy
8,525
+2,521
+42% +$146K 0.02% 586
2016
Q1 		$338K Buy
6,004
+628
+12% +$37.7K 0.02% 691
2015
Q4 		$365K Buy
+5,376
New +$352K 0.02% 656
2014
Q4 		– Sell
-2,862
Closed -$204K – 893
2014
Q3 		$204K Sell
2,862
-344
-11% -$25.2K 0.01% 903
2014
Q2 		$238K Sell
3,206
-6,571
-67% -$475K 0.02% 880
2014
Q1 		$634K Buy
9,777
+5,648
+137% +$365K 0.05% 369
2013
Q4 		$247K Buy
+4,129
New +$224K 0.02% 586

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

FDx Advisors's AZN Position: Q1 2026 in Review

FDx Advisors reduced its AstraZeneca (AZN) stake by 5.2% in Q1 2026, selling an estimated $48.6K and leaving 4,554 shares worth $898K. The position accounts for 0.29% of the portfolio, ranked #64.

FDx Advisors first reported a position in AZN in Q4 2013 and has held it in 45 quarters since. The position peaked at $5.42M in Q4 2017. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • FDx Advisors held 4,554 shares of AstraZeneca worth $898K as of Q1 2026.
  • FDx Advisors sold 252 AstraZeneca shares in Q1 2026, an estimated $48.6K.
  • AstraZeneca made up 0.29% of FDx Advisors's portfolio in Q1 2026, its #64 holding.
  • FDx Advisors first reported a position in AstraZeneca in Q4 2013 and has held it in 45 quarters since.
  • FDx Advisors's AstraZeneca position peaked at $5.42M in Q4 2017.
  • 1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on FDx Advisors's 13F filing for Q1 2026, filed 1 May 2026.